CollPlant Biotechnologies (CLGN) Assets Average (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Assets Average came in at $12.4 million in Q4 2025, up 32.79% YoY from $9.4 million in Q4 2024, and down 21.1% on a QoQ basis from $15.8 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Assets Average (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Assets Average data on file, last reported at $12.4 million in Q4 2025.
- Quarterly Assets Average rose 32.79% year-over-year to $12.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.4 million (up 32.79% YoY) and the FY2025 annual result came in at $14.7 million, down 44.18% from the prior year.
- Assets Average retreated to $12.4 million in Q4 2025, from $15.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $54.3 million in Q3 2021 to a low of $5.4 million in Q1 2021.
- A 5-year average of $28.5 million and a median of $24.2 million in 2021 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 817.14% — and 2024, when it tumbled 65.61%.
- Tracing CLGN's Assets Average over 5 years: stood at $52.4 million in 2021, then slipped by 25.3% to $39.2 million in 2022, then sank by 56.38% to $17.1 million in 2023, then sank by 45.17% to $9.4 million in 2024, then jumped by 32.79% to $12.4 million in 2025.
- The last three Assets Average figures came in at $12.4 million (Q4 2025), $15.8 million (Q3 2025), and $9.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.44 Mn |
| Sep 30, 2025 | 15.76 Mn |
| Dec 31, 2024 | 9.37 Mn |
| Sep 30, 2024 | 13.29 Mn |
| Jun 30, 2024 | 13.30 Mn |
| Mar 31, 2024 | 17.08 Mn |
| Dec 31, 2023 | 17.08 Mn |
| Sep 30, 2023 | 20.80 Mn |
| Jun 30, 2023 | 38.66 Mn |
| Mar 31, 2023 | 36.76 Mn |
| Dec 31, 2022 | 39.16 Mn |
| Sep 30, 2022 | 42.49 Mn |
| Jun 30, 2022 | 46.57 Mn |
| Mar 31, 2022 | 49.97 Mn |
| Dec 31, 2021 | 52.43 Mn |
| Sep 30, 2021 | 54.33 Mn |
| Jun 30, 2021 | 27.54 Mn |
| Mar 31, 2021 | 5.45 Mn |
| Dec 31, 2020 | 11.81 Mn |
| Sep 30, 2020 | 11.86 Mn |